Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...
ComboMATCH trials will use Exact Sciences' (EXAS) new OncoExTra™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday ...
Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results